Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Low genetic barrier to large increases in HIV-1 cross-resistance to protease inhibitors during salvage therapy.

Antiviral therapy - 1 Jan 2006

Morand-Joubert Laurence, Charpentier Charlotte, Poizat Gwendoline, Chêne Geneviève, Dam Elisabeth, Raguin Gilles, Taburet Anne-Marie, Girard Pierre-Marie, Hance Allan J, Clavel François

Abstract excerpt

HIV-1 resistance to protease inhibitors (PIs) is characterized by extensive cross-resistance within this drug class. Some PIs, however, appear less affected by cross-resistance and are often prescribed in salvage therapy regimens for patients who have failed previous PI treatment. To examine the capacity of HIV-1 to adapt to these treatment changes, we have followed the evolution of HIV-1 protease genotypes and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Administration Schedule
Share to Drug Resistance, Multiple, Viral

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Evolution, Molecular

Share to HIV Infections

Share to HIV Protease

Share to HIV Protease Inhibitors

Share to Salvage Therapy

Source

Identifiers

PMID: 16640095

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Low genetic barrier to large increases in HIV-1 cross-resistance to protease inhibitors during salvage therapy.PMID 16640095Read ↗

Protease inhibitor resistance update: where are we now?Semantic proximity Read ↗

Amprenavir-resistant HIV-1 exhibits lopinavir cross-resistance and reduced replication capacity.Semantic proximity Read ↗

Acquisition of multi-PI (protease inhibitor) resistance in HIV-1 in vivo and in vitro.Semantic proximity Read ↗

International perspectives on antiretroviral resistance. Resistance to protease inhibitors.Semantic proximity Read ↗

Resistance to protease inhibitors.Semantic proximity Read ↗

Cross-resistance patterns among HIV protease inhibitors.Semantic proximity Read ↗

Comparison of protease genotype and phenotype in HIV-1 infected patients exposed to more than one protease inhibitor.Semantic proximity Read ↗

Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: a survey of over 6000 samples.Semantic proximity Read ↗

HIV-1 protease mutations and protease inhibitor cross-resistance.Semantic proximity Read ↗

Evolution of primary protease inhibitor resistance mutations during protease inhibitor salvage therapy.Semantic proximity Read ↗

Analysis of HIV cross-resistance to protease inhibitors using a rapid single-cycle recombinant virus assay for patients failing on combination therapies.Semantic proximity Read ↗

Improving lopinavir genotype algorithm through phenotype correlations: novel mutation patterns and amprenavir cross-resistance.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.